https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18998 Wed 20 May 2020 07:08:07 AEST ]]> Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22946 Wed 11 Apr 2018 16:42:13 AEST ]]> Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14183 Wed 11 Apr 2018 13:18:25 AEST ]]> Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> Tailoring adjuvant endocrine therapy for premenopausal breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32778 Wed 07 Feb 2024 16:54:46 AEDT ]]> Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47747 Tue 21 Mar 2023 19:00:49 AEDT ]]> Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25887 Thu 21 Jul 2022 15:37:04 AEST ]]> Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24426 Thu 04 Nov 2021 10:39:39 AEDT ]]> Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32260 Thu 01 Jun 2023 10:46:47 AEST ]]> Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7415 Sat 24 Mar 2018 08:40:26 AEDT ]]> Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8213 Sat 24 Mar 2018 08:36:20 AEDT ]]> Adjuvant ovarian suppression in premenopausal breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16697 Sat 24 Mar 2018 08:06:52 AEDT ]]> Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17176 Sat 24 Mar 2018 08:06:32 AEDT ]]> Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21393 = 30 kg/m²) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m²), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m²) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. Conclusion: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.]]> Sat 24 Mar 2018 08:05:04 AEDT ]]> Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21497 Sat 24 Mar 2018 08:03:39 AEDT ]]> Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17404 Sat 24 Mar 2018 08:01:40 AEDT ]]> Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5450 Sat 24 Mar 2018 07:48:10 AEDT ]]> Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5363 Sat 24 Mar 2018 07:43:57 AEDT ]]> Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29018 P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.]]> Sat 24 Mar 2018 07:31:09 AEDT ]]> Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27579 Sat 24 Mar 2018 07:23:42 AEDT ]]> Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4800 Sat 24 Mar 2018 07:20:39 AEDT ]]> Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23220 Sat 24 Mar 2018 07:10:38 AEDT ]]> Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23908 Sat 24 Mar 2018 07:10:02 AEDT ]]> Treatment-induced symptoms, depression and age as predictors of sexual problem in premenopausal women with early breast cancer receiving adjuvant endocrine therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41881 Mon 15 Aug 2022 14:09:04 AEST ]]> Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44148 Mon 10 Oct 2022 09:17:25 AEDT ]]> Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30333 Fri 01 Apr 2022 09:24:55 AEDT ]]> Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29891 Fri 01 Apr 2022 09:22:24 AEDT ]]>